BLC
AMPH icon

Brown, Lisle/Cummings’s Amphastar Pharmaceuticals AMPH Stock Holding History

Brown, Lisle/Cummings’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$545 Hold
27
– – ﹤0.01% 1017
2026
Q1 		$529 Buy
+27
New +$661 ﹤0.01% 982

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Brown, Lisle/Cummings's AMPH Position: Q2 2026 in Review

Brown, Lisle/Cummings held its Amphastar Pharmaceuticals (AMPH) position steady in Q2 2026 at 27 shares worth $545. The position accounts for ﹤0.01% of the portfolio, ranked #1017.

Brown, Lisle/Cummings first reported a position in AMPH in Q1 2026 and has held it in 2 quarters since. 211 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Brown, Lisle/Cummings held 27 shares of Amphastar Pharmaceuticals worth $545 as of Q2 2026.
  • Brown, Lisle/Cummings left its Amphastar Pharmaceuticals share count unchanged in Q2 2026.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q2 2026, its #1017 holding.
  • Brown, Lisle/Cummings first reported a position in Amphastar Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 211 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q2 2026, filed 2 Sep 2026.